Haleon (LON:HLN) Trading 0.3% Higher – Here’s Why

Haleon plc (LON:HLN)’s share price rose 0.3% during trading on Wednesday . The stock traded as high as GBX 336.40 and last traded at GBX 334.47. 36,930,695 shares changed hands during trading, an increase of 25% from the average session volume of 29,557,242 shares. The stock had previously closed at GBX 333.30.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Berenberg Bank restated a “buy” rating and set a GBX 512 target price on shares of Haleon in a report on Thursday, April 30th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 370 price target on shares of Haleon in a research note on Thursday, April 30th. Finally, Jefferies Financial Group lowered their price objective on Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of GBX 398.67.

Haleon Stock Down 0.2%

The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The company has a market capitalization of £29.47 billion, a P/E ratio of 18.01, a PEG ratio of 1.49 and a beta of 0.25. The firm has a 50-day moving average price of GBX 341.26 and a two-hundred day moving average price of GBX 365.

Insider Buying and Selling

In related news, insider Brian McNamara sold 704,974 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total transaction of £2,594,304.32. 0.01% of the stock is currently owned by insiders.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.